Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'ai Jiedu Fang is a traditional Chinese medicine (TCM) formulation composed of multiple herbal and animal-derived ingredients. It is utilized in clinical settings for the treatment of various malignant tumors, including hepatocellular carcinoma (HCC), lung cancer, and colorectal cancer. Research indicates its anti-tumor effects are mediated through several mechanisms, such as reducing cell survival, inducing apoptosis, and stimulating autophagy via the AKT/mTOR pathway in HCC. It also influences immune cell infiltration and gene transcription in lung cancer, and in colorectal cancer, it has been shown to inhibit tumor growth by modulating gut microbiota, regulating intestinal microecology, and restoring inflammation. Key active components identified in the formula include quercetin, cholesterol, jaceosidine, eupafolin, and oleanolic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'ai Jiedu Fang.